| Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice MA Hoelscher, S Garg, DS Bangari, JA Belser, X Lu, I Stephenson, ... The Lancet 367 (9509), 475-481, 2006 | 266 | 2006 |
| Adenoviral vector immunity: its implications and circumvention strategies Y S Ahi, D S Bangari, S K Mittal Current gene therapy 11 (4), 307-320, 2011 | 226 | 2011 |
| Current strategies and future directions for eluding adenoviral vector immunity DS Bangari, SK Mittal Current gene therapy 6 (2), 215-226, 2006 | 224 | 2006 |
| Development of nonhuman adenoviruses as vaccine vectors DS Bangari, SK Mittal Vaccine 24 (7), 849-862, 2006 | 217 | 2006 |
| Adenovirus receptors and their implications in gene delivery A Sharma, X Li, DS Bangari, SK Mittal Virus research 143 (2), 184-194, 2009 | 171 | 2009 |
| Keratinocyte-derived chemokines orchestrate T-cell positioning in the epidermis during vitiligo and may serve as biomarkers of disease JM Richmond, DS Bangari, KI Essien, SD Currimbhoy, JR Groom, ... Journal of Investigative Dermatology 137 (2), 350-358, 2017 | 161 | 2017 |
| Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder S Abraham, DW Knapp, L Cheng, PW Snyder, SK Mittal, DS Bangari, ... Clinical cancer research 12 (2), 353-360, 2006 | 156 | 2006 |
| Decreased tumorigenic potential of EphA2-overexpressing breast cancer cells following treatment with adenoviral vectors that express EphrinA1 LW Noblitt, DS Bangari, S Shukla, DW Knapp, S Mohammed, MS Kinch, ... Cancer gene therapy 11 (11), 757-766, 2004 | 153 | 2004 |
| CNS-accessible inhibitor of glucosylceramide synthase for substrate reduction therapy of neuronopathic Gaucher disease J Marshall, Y Sun, DS Bangari, E Budman, H Park, JB Nietupski, A Allaire, ... Molecular Therapy 24 (6), 1019-1029, 2016 | 102 | 2016 |
| Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease J Marshall, KM Ashe, D Bangari, KA McEachern, WL Chuang, J Pacheco, ... PloS one 5 (11), e15033, 2010 | 99 | 2010 |
| Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models C Hotz, TR Wagenaar, F Gieseke, DS Bangari, M Callahan, H Cao, ... Science translational medicine 13 (610), eabc7804, 2021 | 95 | 2021 |
| Adenoviral vector-based strategies for cancer therapy A Sharma, M Tandon, DS Bangari, SK Mittal Current drug therapy 4 (2), 117-138, 2009 | 95 | 2009 |
| Efficacy of enzyme and substrate reduction therapy with a novel antagonist of glucosylceramide synthase for Fabry disease KM Ashe, E Budman, DS Bangari, CS Siegel, JB Nietupski, B Wang, ... Molecular medicine 21, 389-399, 2015 | 93 | 2015 |
| Iminosugar-based inhibitors of glucosylceramide synthase increase brain glycosphingolipids and survival in a mouse model of Sandhoff disease KM Ashe, D Bangari, L Li, MA Cabrera-Salazar, SD Bercury, JB Nietupski, ... PLoS One 6 (6), e21758, 2011 | 91 | 2011 |
| A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells E Seung, Z Xing, L Wu, E Rao, V Cortez-Retamozo, B Ospina, L Chen, ... Nature 603 (7900), 328-334, 2022 | 84 | 2022 |
| Comparative transduction efficiencies of human and nonhuman adenoviral vectors in human, murine, bovine, and porcine cells in culture DS Bangari, S Shukla, SK Mittal Biochemical and biophysical research communications 327 (3), 960-966, 2005 | 77 | 2005 |
| Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models KV Kalnin, T Plitnik, M Kishko, J Zhang, D Zhang, A Beauvais, ... npj Vaccines 6 (1), 61, 2021 | 67 | 2021 |
| Porcine adenoviral vectors evade preexisting humoral immunity to adenoviruses and efficiently infect both human and murine cells in culture DS Bangari, SK Mittal Virus research 105 (2), 127-136, 2004 | 63 | 2004 |
| Comparative analysis of vector biodistribution, persistence and gene expression following intravenous delivery of bovine, porcine and human adenoviral vectors in a mouse model A Sharma, DS Bangari, M Tandon, A Pandey, H HogenEsch, SK Mittal Virology 386 (1), 44-54, 2009 | 60 | 2009 |
| Effective clearance of GL-3 in a human iPSC-derived cardiomyocyte model of Fabry disease JM Itier, G Ret, S Viale, L Sweet, D Bangari, A Caron, F Le-Gall, ... Journal of inherited metabolic disease 37, 1013-1022, 2014 | 56 | 2014 |
